Abstract
Cutaneous anergy in SLE patients results from disease activity and/or immunosuppressive treatment (IT). The aim of this study was to evaluate purified protein derivative (PPD) reaction in SLE patients. A total of 145 patients and 20 controls were studied. Five units of PPD were applied on day 0, and skin reaction was measured after 3 (PPD1) and 6 (PPD2) days. A booster was applied (day 14), and the reaction was measured after 3 (PPD3) and 6 (PPD4) days.
Non-parametricANOVA test and unpaired Student's t-test were performed. Forty patients (group I) were inactive (MexSLEDAI 3), receiving no IT (at least 3 months previous to the PPD test); 39 (group II) were inactive receiving IT; 24 (group III) were active without IT, and 42 (group IV) were active with IT. Active patients had lower PPD1 (group III, 1.4 ± 0.9; group IV, 0.6 ± 0.5) than inactive patients (group I, 8.4 ± 2.3; group II, 5.1 ± 1.9) and than controls (9.4 ± 3; P ≤ 0.001). Group IV had lower delayed response (PPD2 = 0.3 ± 0.3) than inactive groups (group I, 2.6 ± 0.9; group II, 3.1 ± 0.8) and than controls (7.9 ± 2.5; P ≤ 0.001). Group III had lower delayed reaction P ≤ 0.001).
Active SLE patients, receiving or not receiving IT, had lower skin response to PPD than inactive patients and controls.
Keywords
Get full access to this article
View all access options for this article.